pharmadog

News

when

Latest
Archive

by source

All Sources
Sources Page

Jobs

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

made by humans and a good dog

home
jobs
news
search

calendar

24,927 catalysts · 5,282 approval · 5,000 device 510k · 4,728 grant · 3,126 8k filing · 2,000 device pma · 2,000 device recall

★ save view ↓export CSV

next 91 dayslessmore

MonWedFri

view

agenda month

sort

soonest latest type sponsor alpha

from 2023-04-28×clear all

type

approval5,282
device 510k5,000
grant4,728
8k filing3,126
device pma2,000
device recall2,000
recall1,126

device adverse event1,000

earnings583

phase 2 completion172

therapy area

Oncology148
Infectious Disease46
Cardiology37
Immunology35
Dermatology31
Pulmonology22
Women's Health19
Ophthalmology16
Pain15

Week of Oct 16, 2023

›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

Sponsor: APOTEX. Form: TABLET. Route: ORAL

full page →tramadol hydrochloride ER →fda approvals ↗

›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

Sponsor: APOTEX. Form: TABLET. Route: ORAL

full page →tramadol hydrochloride ER →fda approvals ↗

›Oct 19, 2023approval1028d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

Sponsor: APOTEX. Form: TABLET. Route: ORAL

full page →tramadol hydrochloride ER →fda approvals ↗

Week of Oct 23, 2023

›Oct 23, 2023approval1024d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

full page →pembrolizumab →fda approvals ↗

›Oct 23, 2023approval

Week of Oct 30, 2023

›Oct 30, 2023approval1017d agoONDANSETRON — FDA approvalSandoz Inc

Sponsor: IPCA LABS LTD. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL

full page →fda approvals ↗

›Oct 30, 2023approval

Week of Nov 6, 2023

›Nov 6, 2023approval1010d agoIDARUBICIN HYDROCHLORIDE — FDA approvalIDARUBICIN HYDROCHLORIDE

Sponsor: PFIZER. Form: SOLUTION. Route: INTRAVENOUS

full page →IDARUBICIN HYDROCHLORIDE →fda approvals ↗

›Nov 7, 2023approval

Week of Nov 13, 2023

›Nov 14, 2023approval1002d agoRINVOQ (UPADACITINIB) — FDA approvalupadacitinib tartrate ER

Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →upadacitinib tartrate ER →fda approvals ↗

›Nov 15, 2023approval

← prev

page 9 of 499

1024d ago

BUDESONIDE — FDA approvalbudesonide DR

Sponsor: RISING. Form: CAPSULE, DELAYED RELEASE. Route: ORAL

full page →budesonide DR →fda approvals ↗

›Oct 23, 2023approval1024d agoOSELTAMIVIR PHOSPHATE — FDA approvalOSELTAMIVIR PHOSPHATE

Sponsor: AJANTA PHARMA LTD. Form: FOR SUSPENSION. Route: ORAL

full page →OSELTAMIVIR PHOSPHATE →fda approvals ↗

›Oct 23, 2023approval1024d agoOSELTAMIVIR PHOSPHATE — FDA approvalOSELTAMIVIR PHOSPHATE

Sponsor: AJANTA PHARMA LTD. Form: FOR SUSPENSION. Route: ORAL

full page →OSELTAMIVIR PHOSPHATE →fda approvals ↗

›Oct 23, 2023approval1024d agoAMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approvalamoxicillin

Sponsor: SANDOZ INC. Form: FOR SUSPENSION. Route: ORAL

full page →amoxicillin →fda approvals ↗

›Oct 25, 2023approval1022d agoURSODIOL — FDA approvalURSODIOL

Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

full page →URSODIOL →fda approvals ↗

›Oct 26, 2023approval1021d agoVABYSMO (FARICIMAB-SVOA) — FDA approvalfaricimab

Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INTRAVITREAL

full page →faricimab →fda approvals ↗

›Oct 26, 2023approval1021d agoOMVOH (MIRIKIZUMAB-MRKZ) — FDA approvalmirikizumab

Sponsor: ELI LILLY AND CO. Form: INJECTABLE. Route: SUBCUTANEOUS

full page →mirikizumab →fda approvals ↗

›Oct 27, 2023approval1020d agoSCOPOLAMINE — FDA approvalRiconpharma LLC

Sponsor: PADAGIS US. Form: SYSTEM. Route: TRANSDERMAL

full page →fda approvals ↗

›Oct 27, 2023approval1020d agoIBANDRONATE SODIUM — FDA approvalIBANDRONATE SODIUM

Sponsor: APOTEX INC. Form: TABLET. Route: ORAL

full page →IBANDRONATE SODIUM →fda approvals ↗

1017d ago

SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval(empagliflozin + metformin hydrochloride ER)

Sponsor: BOEHRINGER INGELHEIM. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →(empagliflozin + metformin hydrochloride ER) →fda approvals ↗

›Oct 30, 2023approval1017d agoGLYXAMBI (EMPAGLIFLOZIN) — FDA approval(empagliflozin + linagliptin)

Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL

full page →(empagliflozin + linagliptin) →fda approvals ↗

›Oct 30, 2023approval1017d agoSYNJARDY (EMPAGLIFLOZIN) — FDA approvalSYNJARDY

Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL

full page →SYNJARDY →fda approvals ↗

›Oct 30, 2023approval1017d agoTRIJARDY XR (EMPAGLIFLOZIN) — FDA approval(empagliflozin + linagliptin + metformin hydrochloride) ER

Sponsor: BOEHRINGER INGELHEIM. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →(empagliflozin + linagliptin + metformin hydrochloride) ER →fda approvals ↗

›Oct 31, 2023approval1016d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

›Oct 31, 2023approval1016d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

full page →pembrolizumab →fda approvals ↗

›Oct 31, 2023approval1016d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

full page →pembrolizumab →fda approvals ↗

›Oct 31, 2023approval1016d agoIDACIO (ADALIMUMAB-AACF) — FDA approvalIDACIO

Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: SUBCUTANEOUS

full page →IDACIO →fda approvals ↗

›Oct 31, 2023approval1016d agoWEZLANA (USTEKINUMAB-AUUB) — FDA approvalWEZLANA

Sponsor: AMGEN INC. Form: INJECTABLE. Route: INTRAVENOUS, SUBCUTANEOUS

full page →WEZLANA →fda approvals ↗

›Oct 31, 2023approval1016d agoWEZLANA (USTEKINUMAB-AUUB) — FDA approvalWEZLANA

Sponsor: AMGEN INC. Form: INJECTABLE. Route: INTRAVENOUS, SUBCUTANEOUS

full page →WEZLANA →fda approvals ↗

›Nov 1, 2023approval1015d agoVOQUEZNA (VONOPRAZAN FUMARATE) — FDA approvalvonoprazan fumarate

Sponsor: PHATHOM. Form: TABLET. Route: ORAL

full page →vonoprazan fumarate →fda approvals ↗

›Nov 1, 2023approval1015d agoUZEDY (RISPERIDONE) — FDA approvalDelpor Inc

Sponsor: TEVA. Form: SUSPENSION, EXTENDED RELEASE. Route: SUBCUTANEOUS

full page →fda approvals ↗

›Nov 3, 2023approval1013d agoHUMIRA (ADALIMUMAB) — FDA approvaladalimumab

Sponsor: ABBVIE INC. Form: VIAL

full page →adalimumab →fda approvals ↗

›Nov 3, 2023approval1013d agoDOVATO (DOLUTEGRAVIR SODIUM) — FDA approvalViiV Healthcare Company

Sponsor: VIIV HLTHCARE. Form: TABLET. Route: ORAL

full page →fda approvals ↗

1009d ago

KEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

full page →pembrolizumab →fda approvals ↗